An observational study in Epidermolysis Bullosa Dystrophica, sponsored by Stanford University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Epidermolysis Bullosa Dystrophica with a site in United States — 12 open to participants now, 16 under way, 4 of them phase 3. Epidermolysis Bullosa Dystrophica · United States.
Among the 45 studies in Epidermolysis Bullosa Dystrophica with a site in United States, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2009, is one of 13 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 6th registered.
78 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 21 are open to participants now.
Browse Epidermolysis Bullosa Dystrophica studies →12 of the 45 studies in Epidermolysis Bullosa Dystrophica with a site in United States are open now. Recruiting first, the newest first:
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
M. Peter Marinkovich · Sites in United States
Ages 6+
Abeona Therapeutics, Inc · Sites in United States
Krystal Biotech, Inc. · Sites in United States
Ages 6 mo+
Chiesi Farmaceutici S.p.A. · Sites in United States, France, Germany and 3 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Epidermolysis Bullosa Dystrophica studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 18 · Phase 3 8
First in 2007; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 35 across 18 observational studies indexed under Epidermolysis Bullosa Dystrophica.
Median enrollment 8 across the 32 interventional studies, 29 across the 13 observational. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 45 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,169 studies on the registry; 431 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Stanford University has 5 studies filed under Epidermolysis Bullosa Dystrophica — fewer than ten, so there is no comparison to draw.
4 of the studies in Epidermolysis Bullosa Dystrophica with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016750Phase 3Krystal Biotech, Inc.A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | 2026-12 |
| NCT06892639Phase 3Castle Creek Biosciences, LLC.Evaluation of D-Fi for the Treatment of Wounds Due to DEB | 2027-09 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Epidermolysis Bullosa Dystrophica with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
We will obtain a detailed medical history and will perform a skin examination and brief physical exam. Photographs may be taken. We will ask questions about the size and duration wounds.
LAB TESTS We will draw blood to determine overall health status to include Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) testing. Genetic testing may also be performed.
BIOPSIES Biopsies may be collected to check for Collagen 7 and for antibodies to Collagen 7.
Based on the results obtained, it may be possible to identify patients who would qualify to participate in current or future clinical trials.
Patients diagnosed with RDEB by a local dermatologist who are medically stable enough to travel to Stanford University Medical Center. Patients should also be at least 7 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Medical instability limiting ability to travel to Stanford University Medical Center
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa for future studies
Time frame: 10 years
Started Nov 2009 (actual). Primary completion is estimated for Dec 2029, 241 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epidermolysis Bullosa Dystrophica →